Abbott, which acquired Madison’s Exact Sciences earlier this year, reported third-quarter sales of $13.01 billion, a 14.5% increase over the same quarter of 2025, and 7% sales growth on a comparable basis.
The figures were reported this morning during Abbott’s third quarter investor call.
The global healthcare company also reported diluted earnings per share of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items.
Abbott projected full-year 2026 comparable sales growth of approximately 6% and said it had tightened the range of its guidance on full year 2026 earnings per share to between $5.50 and $5.55.
The company said comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23.
Abbott said comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott’s Structural Heart business received as part of a multi-year agreement with a competitor.
Abbott management said it believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business.
“Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio,” Robert B. Ford, chairman and chief executive officer of Abbott, said in a press release. “With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead.”
During the quarter, Abbott introduced SimpleScreen CRC, a new blood-based colorectal cancer screening test for adults aged 45 and older that has been approved by the Food and Drug Administration.
The company also announced that Cologuard Plus, the noninvasive colorectal cancer screen developed by Exact Sciences, had reached an important milestone on its way to being marketed in Europe.
The test received the CE Mark under the European Union’s In Vitro Diagnostic Medical Devices Regulation.
The company plans to introduce Cologuard Plus in select European markets.
